The ABCC4 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from human SK-HEP-1 liver adenocarcinoma cells. This product features targeted disruption of the ABCC4 gene, which encodes the multidrug resistance protein 4 (MRP4). As a polyclonal knockout pool, it provides a genetically diverse loss-of-function model suitable for high-throughput and mechanistic studies without clonal selection artifacts.
The SK-HEP-1 host cell line originates from ascites of a patient with liver adenocarcinoma and exhibits endothelial-like characteristics, making it a valuable model for hepatocellular carcinoma and multidrug resistance research. Its unique phenotype allows investigation of both epithelial and mesenchymal properties in cancer, and its widespread use in pharmacology underscores its relevance for drug transport and resistance studies.
ABCC4/MRP4 functions as an ATP-dependent efflux transporter for a broad range of substrates, including nucleoside analogs, cyclic nucleotides (cAMP, cGMP), prostaglandins (PGE2), and bile acids. Its expression is positively regulated by the transcription factor NRF2 in response to oxidative stress and by nuclear receptors PXR and CAR. MRP4 also modulates intracellular cAMP levels and PGE2 secretion, thereby influencing signaling pathways linked to inflammation and cell proliferation. The transporter interacts with scaffolding proteins such as PDZK1 and EBP50 for proper membrane localization and forms functional complexes with related efflux pumps like MRP2.
In the context of SK-HEP-1 cells, ABCC4 disruption attenuates the efflux of key substrates, including methotrexate and cAMP, leading to altered intracellular signaling and increased chemosensitivity. This knockout model is particularly significant for deciphering the role of MRP4 in hepatocellular carcinoma chemoresistance and for understanding how transporter-mediated export of inflammatory mediators impacts tumor progression. The endothelial-like background further enables studies on vascular mimicry and drug permeability.
This polyclonal ABCC4 knockout cell product is intended for a broad range of applications, such as drug transporter kinetics, chemoresistance mechanism elucidation, and pharmacokinetic profiling. Researchers can employ functional assays including calcein-AM efflux, intracellular cAMP measurement, PGE2 ELISA, and flow cytometry-based substrate accumulation to quantify MRP4 activity. Additionally, the model supports cytotoxicity testing with agents like methotrexate and investigation of migration/invasion behavior. For further information, please contact Ascent Research.
